Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
Loxapine Relative adverse effects - a rough guide Smoking and psychotropic drugs
Lumateperone Antipsychotics - minimum effective doses Equivalent doses Psychotropics in overdose Quick reference for licensed maximum doses Relative adverse effects - a rough guide Switching antipsychotics
Lung disease, interstitial
Lurasidone Antipsychotics - minimum effective doses bipolar depression cardiac safety of clozapine augmentation Equivalent doses in overdose QTc prolongation Quick reference for licensed maximum doses Relative adverse effects - a rough guide
Lymphocytes, psychotropic agent effects
Maintenance for drug dependence, opioid substitution treatment
Maintenance phase, children and adolescents with depression
Maintenance treatment bipolar disorder psychotic depression schizophrenia
major depressive disorder (MDD) 335-361 bipolar depression comparison older people
Malabsorptive surgical procedures, bariatric surgery
Management of adverse effects of hormone replacement therapy (HRT)
Management of antipsychotic-induced hyperprolactinaemia.
Management of antipsychotic-induced orthostatic hypotension
Management of psychiatric disorders in people with 22q11.2 deletion syndrome.
Management of QT prolongation in patients receiving antipsychotic drugs
Management of sexual adverse effects
Management with alternative substances
Managing behavioural and psychological symptoms of dementia
Managing treatment-resistant depression
Mania acute/hypomania antipsychotic treatments benzodiazepines lithium treatment people living with human immunodeficiency virus treatment in children and adolescents treatment strategies valproate treatment
Mania: other possible treatments
Mania: suggested drug doses
Mania (bipolar disorder) antipsychotics benzodiazepines carbamazepine lithium treatment manic switch, depression in children and adolescents treatment options valproate treatment
Maximum dose
Maximum doses of antipsychotics according to European Medicines Agency labelling
Mean cell haemoglobin concentration, psychotropic agent effects
Mechanism of action
Medical menopause, assessing premenstrual syndrome/premenstrual dysphoric disorder
Medical menopause using gonadotrophin-releasing hormone agonists
Medication Adherence Rating Scale (MARS) 931